Pharmatest Services Ltd (Pharmatest) is a preclinical contract research organization specialized in fast and flexible pharmacodynamic research for drug discovery and development of biochemicals in the following therapeutic areas:
- osteoporosis
- cancer (especially cancer-induced bone disease and cancer metastasis)
- osteoarthritis
- urological diseases
- disorders of the lower urinary tract
We offer you a comprehensive package of highly specialized disease models and drug efficacy testing services ranging from our unique in vitro bone cell efficacy assays to in vivo models. We are specialized in providing our customers with assistance in disease areas where there are limited, or no other commercial services available. Our focus is on bone biology and diseases with unmet clinical needs, such as cancer metastasis and multiple myeloma. We have also developed a highly specialized platform for testing potential therapies against disorders of the lower urinary tract (LUTS).
Our services have been developed with just one goal in mind – to make your drug discovery faster and more effective. Partnering with Pharmatest gives you a flexible access to latest tools for lead candidate validation and proof-of-concept studies. We can also help you test your new drug candidates for possible adverse effects on or assist you in obtaining FDA approval (regulatory study) for your osteoporosis drug candidate.
Specialties
Preclinical Research, Drug Discovery, Drug Development, Osteoporosis, Cancer, Osteoarthritis, Urology, Inflammation, Hormone Action, Safety Testing, Bioinformatics
Pharmatest Services Ltd Activity on LinkedIn
-
Pharmatest Services Ltd ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that ValiFinn Oy, its wholly owned subsidiary, has acquired from Pharmatest Services Oy (“Pharmatest”) of Oulu, Finland, its biomarkers business unit together with 5 families of patents and patent applications and related intellectual property (“IP”). Additional information in an Outsourcing Pharma article at http://www.outsourcing-pharma.com/Clinical-Development/ValiRx-expands-into-services-with-biomarker-business-buy
